Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186
Volume 4, Issue 5
Displaying 1-10 of 10 articles from this issue
Policy Forum
  • Keisuke Naito, Kan Kikuchi, Yu Watanabe, Tomoyo Narita
    2022 Volume 4 Issue 5 Pages 253-258
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: October 20, 2022
    JOURNAL FREE ACCESS

    The Japanese government recommended hospitalization of patients on dialysis once they tested positive because of their high COVID-19 mortality rate and definite need for periodic dialysis. However, after experiencing the Delta variant surge, strategic changes towards outpatient care for mild or asymptomatic cases, along with strengthening emergency preparedness were needed. Facing the Omicron surge, the Tokyo Metropolitan Government introduced two novel schemes: i) a temporary medical facility with a dialysis center for infected patients on hemodialysis, which started admitting patients on dialysis on January 20, 2022, to provide additional bed capacity and access to hemodialysis and ii) a transportation scheme for patients who need travel to maintenance dialysis facilities from their homes, which was introduced on February 5. The Tokyo Metropolitan Government, cooperating with some nephrology experts, announced these schemes and urged local dialysis facilities to change strategies, providing information regarding infection prevention measures and treatments in online seminars on February 3 and 7. Consequently, promoting outpatient care did not lead to an increase in the case fatality ratio (CFR) in patients on dialysis with COVID-19 in Tokyo during the first Omicron surge (January 7 to February 10, 8.2%; February 11 to March 31, 5.5%). Furthermore, after an additional online seminar on July 20, the CFR dramatically declined in the second Omicron surge (July 8 to September 8, 1.2%). Implementation of public health intervention and careful communication with local dialysis facilities were both crucial to the strategic changes. To maintain essential health services, emergency preparedness should be cultivated during regular times.

    Download PDF (500K)
Original Article
  • Yasuhide Yamada, Hirotoshi Kobayashi, Kengo Nagashima, Kenichi Sugihar ...
    Article type: research-article
    2022 Volume 4 Issue 5 Pages 259-267
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 23, 2022
    JOURNAL FREE ACCESS

    Although fluoropyrimidine plus oxaliplatin is the standard of care for stage III colon cancer, fluoropyrimidine alone is also recommended for stage III patients in Japanese and other practice guidelines. We assessed efficacy of adjuvant fluoropyrimidine with or without oxaliplatin across a population of patients with stage III colon cancer in the Multi-Institutional Registry of Large Bowel Cancer in Japan. From the registry, we analyzed 6,834 stage III colorectal cancer patients. Approximately 70% of colorectal cancer patients received some form of chemotherapy. Of these, we analyzed those who received adjuvant chemotherapy between 2008 and 2011. Based on the TNM classification, the 5-year overall survival rates of colon and rectal cancer after the covariate adjustment by regimens of adjuvant chemotherapy were 95.7% with fluoropyrimidines and 90.6% with oxaliplatin-combined therapy at stage IIIA (Stratified log-rank P < 0.001), 86.5% and 80.8% at stage IIIB (P < 0.001), and 72.1% and 70.7% at stage IIIC (P < 0.001), respectively. Oxaliplatin did not enhance efficacy with regard to relapse-free survival as well as overall survival. Adjuvant fluoropyrimidine monotherapy and fluoropyrimidine plus oxaliplatin show comparable efficacy benefits for the treatment of stage III of Japanese colon cancer patients. This supports the use of fluoropyrimidine alone as a standard option for this patient group in Japan.

    Download PDF (1459K)
Correspondence
  • Yoshiki Kusama, Mitsuoki Miyahara, Masahiro Ishikane, Kumiko Suzuki, Y ...
    2022 Volume 4 Issue 5 Pages 268-272
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: October 27, 2022
    JOURNAL FREE ACCESS

    To elucidate the current practices of infectious disease management in home care settings in Japan, we sent a questionnaire to 36 physicians working at 13 clinics that specialize in providing care to patients in their homes or residential care facilities. The questionnaire described three hypothetical scenarios (aspiration pneumonia, pyelonephritis, and neoplastic fever) in older patients with terminal cancer, and 25 respondents answered questions on testing and treatment strategies. Most respondents chose to obtain cultures for aspiration pneumonia (sputum) and for pyelonephritis (urine), although fewer respondents chose to obtain blood cultures. For neoplastic fever, most of respondents elected to continue observation without antibiotic treatment. The most frequently selected antibiotics were cephalosporins and quinolones. The results indicated that most respondents would perform bacterial culture tests before prescribing antibiotics and observe patients when bacterial infections are not suspected. Standardized guidelines are needed to optimize infectious disease management in home care.

    Download PDF (267K)
  • Lingcha Ye, Jia Chen, Qing Qi, Jing Zhou, Chengying Zhu, Yan Jiang, Li ...
    2022 Volume 4 Issue 5 Pages 273-277
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: October 23, 2022
    JOURNAL FREE ACCESS

    Effective health interventions are a priority for future infertility research, and effective interventions in patient-centered care are still needed. A multi-center prospective study was conducted in order to investigate the effects of a physician-nurse partnership (patients receive guidance and health education via online healthcare platforms) on depression and anxiety disorders in infertile women. The women were randomly assigned to a physician-nurse partnership group (n = 90) or a routine treatment group (n = 90). The primary endpoints were self-rating anxiety scale and self-rating depression scale scores. This study also examined the waiting time as an outpatient and the frequency of using online medical platforms. Compared to the routine treatment group, scores on the self-rating anxiety scale (48.4) and the self-rating depression scale (48.0) were significantly lower in the physician-nurse partnership group (p = 0.004, p = 0.001). Moreover, the mean waiting time (3.4) was shorter and online platforms (6.1) were used more frequently in the physician-nurse partnership group than in the routine treatment group (p < 0.001, p < 0.001). These data suggest that a physician-nurse partnership could reduce patients' anxiety, depression, and their waiting time as an outpatient.

    Download PDF (239K)
  • Hanae Sone, Hiromi Ogawa, Ryo Miyaki, On Kato
    2022 Volume 4 Issue 5 Pages 278-281
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 26, 2022
    JOURNAL FREE ACCESS

    The rapid increase in inpatients during the coronavirus disease 2019 (COVID-19) pandemic acutely increased the workload of physicians and nurses caring for severely ill patients. Moreover, family visits were restricted for infection control purposes, and family members were unable to be briefed regarding a patient's condition because they tested positive or they had been in close contact with an infectious patient, thus increasing the burden on the patient's family and the medical staff. Therefore, our psychiatric liaison team intervened by attending briefing sessions for family members and online patient visits while also conducting sessions to provide information about mental health and relaxation sessions for the hospital's nurses to reduce their burden as much as possible. These efforts provided mental support for the patients' families while also reducing the challenges of and the burden on medical staff. If the number of severely ill patients increases rapidly and the burden on patients' families and medical staff increases, then we hope that these efforts will help to provide better psychological support to both families and staff.

    Download PDF (196K)
  • Yuta Tamai, Noritoshi Arai, Makiko Fujitani, Seisaku Kanayama, Masato ...
    2022 Volume 4 Issue 5 Pages 282-284
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 30, 2022
    JOURNAL FREE ACCESS

    Studies have reported that COVID-19 is associated not only with pneumonia but also with cerebrovascular disease. Consequently, medical personnel involved in treating stroke in the emergency medicine setting have been placed in a situation that requires them to provide treatment while always remaining mindful of the possibility of COVID-19. Here, we describe the current state of stroke treatment during the COVID-19 pandemic. Four patients with stroke and concomitant COVID-19 were treated at our facility. We treated 3 patients with cerebral infarction and 1 patient with cerebral venous sinus thrombosis. All 3 patients with cerebral infarction had a poor outcome. This was attributed in part to the poor general condition of the patients due to concomitant COVID-19, as well as to the severity of the major artery occlusion and cerebral infarction. One patient with cerebral venous sinus thrombosis had a good outcome. Anticoagulant therapy was administered at our hospital and resulted in a stable clinical course. Our hospital has worked to establish an examination and treatment system that enables mechanical thrombectomy to be performed even during the COVID-19 pandemic. We devised a protocol showing the steps to be taken from initial treatment to admission to the cerebral angiography room. Our hospital was able to continue accepting requests for emergency admission thanks to the examination and treatment system we established. Up-to-date information should continue to be collected to create examination and treatment systems.

    Download PDF (921K)
Letter
  • Ayako Honda, Toyomitsu Tamura, Hiroko Baba, Haruka Kodoi, Shinichiro N ...
    Article type: letter
    2022 Volume 4 Issue 5 Pages 285-288
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 11, 2022
    JOURNAL FREE ACCESS

    Human resources for health are at the center of healthcare service delivery and play an important role in ensuring the resilience of health systems. Utilizing the results from a case study examining hospital resilience during COVID-19, this article draws on the experience of individual hospital staff during the first and second waves of the pandemic, briefly describes government responses to support human resources for health during the early stages of the pandemic, and argues the importance of constructive discussions about strategies to create an enabling work environment for healthcare providers, both clinical and non-clinical, during future health shocks.

    Download PDF (250K)
  • Ayano Motohashi
    Article type: letter
    2022 Volume 4 Issue 5 Pages 289-291
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 26, 2022
    JOURNAL FREE ACCESS

    Due to the coronavirus disease 2019 (COVID-19) pandemic, we have been conducting polymerase chain reaction (PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at this facility since March 2020. In the early days, the PCR testing system had limited capabilities, so testing had to be conducted manually and only a few tests were conducted. Moreover, we lacked sufficient experience to conduct PCR testing manually, so we struggled with the manual work, which required intense concentration, and we felt pressured not to make mistakes such as allowing contamination. Since we introduced upgraded equipment, new methods, and additional staff for testing and we cooperated with the clinical technologist on the night shift in the Emergency Department, we are currently able to conduct urgent PCR testing on more than 2,000 specimens per month 24 hours a day. We will continue to meet new needs for COVID-19 treatment with the cooperation of other departments.

    Download PDF (246K)
  • Tomoko Sato
    Article type: letter
    2022 Volume 4 Issue 5 Pages 292-293
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: June 06, 2022
    JOURNAL FREE ACCESS

    Hospitals that admit patients with COVID-19 face the challenge of not only dealing with these patients but also balancing normal medical care and hospital management to cope with the challenges posed by the new post-epidemic era. Over the past two years of responding to COVID-19 as a front-line clinical nurse, my colleagues and I have fully appreciated the need to establish a nursing system that is appropriate for the new post-epidemic era. The following four aspects should be emphasized: i) the continuation of thorough infection control measures; ii) exploring new approaches to training for new recruits; iii) ensuring nursing workforce and improving the nursing capacity to cope with patients critically ill with COVID-19; and iv) teamwork and team care to provide nurses with timely psychological assistance.

    Download PDF (453K)
  • Motohiko Sato, Takashi Fukaya, Tatsunori Ogawa, Naoto Nunose, Shigeru ...
    Article type: letter
    2022 Volume 4 Issue 5 Pages 294-295
    Published: October 31, 2022
    Released on J-STAGE: November 20, 2022
    Advance online publication: September 26, 2022
    JOURNAL FREE ACCESS

    The duties of a clinical engineer (CE) during the coronavirus infection 2019 (COVID-19) pandemic were diverse. The original duties of a CE included operation and maintenance of life support equipment used for respiratory therapy, hemodialysis, and extracorporeal membrane oxygenation. The management of life support equipment is critical. The PB-840 ventilator is equipped with a heat sink system that dissipates internal heat through thermal conduction. Therefore, internal contamination is less likely to occur. The exhalation filter used in the PB-840 can be used for up to 15 days. It can be used for long periods of time without maintenance, reducing the risk of infection. The PB-840 is a suitable device for patients with COVID-19. Its use in critically ill patients was determined to be a priority. Thus, use of an appropriate device for infection control requires a proper understanding of and familiarity with the device in question.

    Download PDF (356K)
feedback
Top